ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.00%
US Tech 100
18,178.00
0.83%
S&P 500
5,295.43
0.34%
US Dollar vs CAD
1.3624
-0.21%
Bitcoin
69,979.49
3.29%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Axsome Therapeutics Inc (AXSM)

  7. Axsome Therapeutics Inc (AXSM) News

AXSM

Axsome Therapeutics (AXSM)

Axsome Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AXSM
DateTimeSourceHeadlineSymbolCompany
06/03/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Supports Alzheimer’s & Brain Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
05/30/20246:00AMGlobeNewswire Inc.Axsome Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
05/29/20247:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
05/29/20247:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
05/29/20243:24PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
05/29/20243:23PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
05/29/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024NASDAQ:AXSMAxsome Therapeutics Inc
05/28/20243:28PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
05/28/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) MeetingNASDAQ:AXSMAxsome Therapeutics Inc
05/08/20246:00AMGlobeNewswire Inc.Axsome Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
05/06/20244:20PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AXSMAxsome Therapeutics Inc
05/06/20247:09AMIH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:AXSMAxsome Therapeutics Inc
05/06/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
05/06/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
05/01/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Recognizes May as Mental Health Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
04/15/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:AXSMAxsome Therapeutics Inc
04/10/20246:00AMGlobeNewswire Inc.Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6NASDAQ:AXSMAxsome Therapeutics Inc
04/01/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating DisorderNASDAQ:AXSMAxsome Therapeutics Inc
03/25/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsNASDAQ:AXSMAxsome Therapeutics Inc
03/25/20245:30AMGlobeNewswire Inc.Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyNASDAQ:AXSMAxsome Therapeutics Inc
03/19/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderNASDAQ:AXSMAxsome Therapeutics Inc
03/05/20246:00AMGlobeNewswire Inc.Axsome Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
02/29/20245:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
02/29/20245:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
02/29/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
02/27/20246:00AMGlobeNewswire Inc.Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
02/23/20247:10AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AXSMAxsome Therapeutics Inc
02/20/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
02/20/20246:00AMGlobeNewswire Inc.Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
02/20/20244:37AMIH Market NewsMarket Cautiousness Ahead of Retail Giants’ Earnings; Oil Prices DipNASDAQ:AXSMAxsome Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AXSM

Your Recent History

NASDAQI
SX5510GI
OMX Stockholm Basic Reso...
LSE
EMQP
Emqqemi&eetfacc
AQSE
JADE.GB
Jade Road Investments
BIT
UB26FY
UniCredit Bank
BIT
S28226
Societe Generale Effekten
BIT
F13663
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved